Position in ACLX
as of Mar 31, 2026
· filed May 15, 2026
Position Value
$872,632
New position
Shares Held
7,600
first reported quarter
Ownership
0.013%
of shares outstanding
% of Portfolio
0.17%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Mar 2026
1 quarter on record
Voting authority
Sole 100%
Shared 0%
None 0%
Derivatives in ACLX
reported options exposure · as of Mar 31, 2026CallValue
$114,820
CallShares
1,000
PutValue
$424,834
PutShares
3,700
Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.
Position in Biotechnology
Healthcare · as of Mar 31, 2026CSS LLC/IL holds $14,889,923 across 15 Biotechnology names. ACLX ranks #6 (5.9% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | IONS |
Ionis Pharmaceuticals Inc
|
79,093 | $5,939,093 | |
| 2 | APLS |
Apellis Pharmaceuticals, Inc.
|
42,818 | $1,722,568 | |
| 3 | INCY |
Incyte Corp
|
12,068 | $1,135,840 | |
| 4 | REGN |
Regeneron Pharmaceuticals, Inc.
|
1,170 | $903,988 | |
| 5 | BMRN |
Biomarin Pharmaceutical Inc
|
15,980 | $902,710 | |
| 6 | ACLX |
Arcellx, Inc.
This page
|
7,600 | $872,632 | |
| 7 | EXEL |
Exelixis, Inc.
|
15,879 | $681,050 | |
| 8 | CNTA |
Centessa Pharmaceuticals plc
|
17,000 | $675,240 |
All Filings in ACLX
Export CSV
3 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $424,834 | 3,700 | Put | Sole | 2026-05-15 | |
| 2026-03-31 | $114,820 | 1,000 | Call | Sole | 2026-05-15 | |
| 2026-03-31 | $872,632 | 7,600 | Shares | Sole | 2026-05-15 | |
| No filing history on record for this holder in this stock. | ||||||